Login
Companies $ANRO
$27.12 +$0.00 (0.0%) After hours
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc.

altoneuroscience.com

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −77% (Loss)
vs −$14.2M in Q3 FY2025
  • Jul 13, 2026 Alto raised funds to expand ALTO-207 development The offering was intended to support an additional Phase 3 trial of ALTO-207 as monotherapy for treatment-resistant depression.
  • Apr 1, 2026 Alto deprioritized ALTO-101 in schizophrenia and sought a partner After the trial missed its primary endpoints, Alto said it would focus resources on ALTO-207 and explore partnering for ALTO-101.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support